WuXi NextCODE is restructuring its operations as part of an effort to position the company for future growth, and new collaborations with industry partners. Effective June 23, 2020, the company, now as Genuity Science, is coordinating its operations in the U.S., Iceland and Ireland (where it previously operated as Genomics Medicine Ireland) in order to improve efficiency and collaboration, as well as its offerings and services to customers around the world.

Genuity Science will complete separation from WuXi NextCODE’s Shanghai operations, a process that began in mid-2019 in response to changes in China’s Human Genetic Resource Regulation (HGRAC). Strategic options are being considered for the Shanghai operations going forward, with complete separation expected later in 2020.

As Genuity Science, the company will continue to be a U.S.-headquartered contract genomics and data-sourcing, -analytics and -insights organization – providing global biopharmaceutical partners with therapeutic discovery and development services such as population-scale, disease-specific data sourcing, sequencing, statistical analysis and software tools for analyzing large datasets and artificial intelligence (AI).